|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/06/20 Abiomed Inc 10-Q 12/31/19 85:13M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.29M
2: EX-3.2.1 Articles of Incorporation/Organization or Bylaws HTML 181K
3: EX-3.2.2 Articles of Incorporation/Organization or Bylaws HTML 204K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
79: R1 Document and Entity Information HTML 78K
32: R2 Condensed Consolidated Balance Sheets HTML 122K
22: R3 Condensed Consolidated Balance Sheets HTML 47K
(Parenthetical)
55: R4 Condensed Consolidated Statements of Operations HTML 82K
78: R5 Condensed Consolidated Statements of Comprehensive HTML 49K
Income
31: R6 Condensed Consolidated Statements of Stockholders' HTML 124K
Equity
21: R7 Condensed Consolidated Statements of Cash Flows HTML 123K
54: R8 Nature of Business HTML 29K
80: R9 Basis of Preparation and Summary of Significant HTML 34K
Accounting Policies
58: R10 Net Income Per Share HTML 127K
81: R11 Revenue Recognition HTML 127K
40: R12 Financial Instruments HTML 504K
29: R13 Property and Equipment HTML 63K
59: R14 Goodwill, In-Process Research and Development and HTML 139K
Other Assets
82: R15 Leases HTML 94K
41: R16 Accrued Expenses HTML 59K
30: R17 Stockholders' Equity HTML 165K
57: R18 Stock-Based Compensation HTML 215K
83: R19 Income Taxes HTML 104K
42: R20 Commitments and Contingencies HTML 45K
14: R21 Segment and Enterprise Wide Disclosures HTML 29K
62: R22 Basis of Preparation and Summary of Significant HTML 112K
Accounting Policies (Policies)
69: R23 Net Income Per Share (Tables) HTML 125K
43: R24 Revenue Recognition (Tables) HTML 92K
15: R25 Financial Instruments (Tables) HTML 506K
63: R26 Property and Equipment (Tables) HTML 63K
70: R27 Goodwill, In-Process Research and Development and HTML 138K
Other Assets (Tables)
44: R28 Leases (Tables) HTML 91K
12: R29 Accrued Expenses (Tables) HTML 58K
27: R30 Stockholders' Equity (Tables) HTML 166K
39: R31 Stock-Based Compensation (Tables) HTML 220K
85: R32 Income Taxes (Tables) HTML 99K
61: R33 Computation of Basic and Diluted Net Income Per HTML 54K
Share (Detail)
26: R34 Net Income Per Share - Additional Information HTML 28K
(Detail)
38: R35 Revenue Recognition - Schedule of Categorizes HTML 37K
Revenue by Major Business Line (Detail)
84: R36 Revenue Recognition - Terms - Additional HTML 39K
Information (Detail)
60: R37 Revenue Recognition - Deferred Revenue - HTML 30K
Additional Information (Detail)
28: R38 Cash Equivalents and Marketable Securities HTML 34K
(Detail)
37: R39 Investable Cash Equivalents and Marketable HTML 60K
Securities (Detail)
19: R40 Financial Instruments - Additional Information HTML 44K
(Detail)
50: R41 Schedule of Cross-Currency Rate Swap Derivatives HTML 35K
(Detail)
72: R42 Schedule of Fair Value of Company's Derivative HTML 29K
Instrument (Detail)
65: R43 Financial Instruments Measured at Fair Value HTML 75K
(Detail)
18: R44 Valuation Method Used to Calculate Level 3 HTML 73K
Liabilities Measured at Estimated Fair Value of
Contingent Consideration Related to Acquisition
(Detail)
49: R45 Change in Fair Value of Contingent Consideration HTML 40K
as Determined by Level 3 Inputs (Detail)
71: R46 Components of Property and Equipment (Detail) HTML 50K
64: R47 Goodwill, In-Process Research and Development and HTML 70K
Other Assets - Additional Information (Detail)
20: R48 Carrying Value of Goodwill and Change in Balance HTML 30K
(Detail)
48: R49 Carrying value of In-Process Research and HTML 29K
Development (Detail)
33: R50 Summary of Other Assets (Detail) HTML 34K
24: R51 Equity Method and Other Investments Classified as HTML 34K
Other Assets (Detail)
51: R52 Carrying value of Equity Method and Other HTML 34K
Investments (Detail)
76: R53 Supplemental Balance Sheet Information Related to HTML 33K
Operating Leases (Detail)
34: R54 Leases - Additional Information (Details) HTML 30K
25: R55 Maturities of Operating Lease Liabilities HTML 49K
(Details)
53: R56 Minimum Future Lease Payments (Detail) HTML 45K
77: R57 Accrued Expenses (Detail) HTML 46K
36: R58 Stockholders' Equity - Additional Information HTML 37K
(Detail)
23: R59 Stockholders' Equity - Schedule of Share HTML 35K
Repurchase Activity (Detail)
67: R60 Stockholders' Equity - Schedule of Accumulated HTML 49K
Other Comprehensive Income (Loss) (Detail)
73: R61 Stock-Based Compensation Recognized (Detail) HTML 35K
46: R62 Summary of Stock Option Activity (Detail) HTML 80K
16: R63 Stock-Based Compensation - Additional Information HTML 56K
(Detail)
68: R64 Summary of Weighted Average Grant-Date Fair Values HTML 40K
And Weighted Average Assumptions Used to Calculate
Fair Value of Options Granted (Detail)
74: R65 Summary of Restricted Stock Units Activity HTML 50K
(Detail)
47: R66 Income Taxes - Additional Information (Detail) HTML 34K
17: R67 Differences Between Statutory Income Tax Rate and HTML 49K
Effective Income Tax Rate (Detail)
66: R68 Commitments and Contingencies - Additional HTML 31K
Information (Detail)
75: R69 Segment and Enterprise Wide Disclosures - HTML 40K
Additional Information (Detail)
13: XML IDEA XML File -- Filing Summary XML 155K
45: XML XBRL Instance -- abmd-10q_20191231_htm XML 3.85M
35: EXCEL IDEA Workbook of Financial Reports XLSX 87K
8: EX-101.CAL XBRL Calculations -- abmd-20191231_cal XML 199K
9: EX-101.DEF XBRL Definitions -- abmd-20191231_def XML 414K
10: EX-101.LAB XBRL Labels -- abmd-20191231_lab XML 1.15M
11: EX-101.PRE XBRL Presentations -- abmd-20191231_pre XML 904K
7: EX-101.SCH XBRL Schema -- abmd-20191231 XSD 156K
56: JSON XBRL Instance as JSON Data -- MetaLinks 322± 521K
52: ZIP XBRL Zipped Folder -- 0001564590-20-003682-xbrl Zip 273K
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A), AS ADOPTED
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Todd A. Trapp, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the period ended December 31, 2019 of ABIOMED, Inc.
2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;
3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and
(d) Disclosed in this Report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: February 6, 2020 |
|
/s/ TODD A. TRAPP |
|
|
|
|
|
|
|
Vice President and Chief Financial Officer (Principal Financial Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/6/20 | 8-K | ||
| For Period end: | 12/31/19 | 11-K, SD | ||
| List all Filings | ||||